August 1, 2023
EQRx, Inc. Investigation
We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of EQRx, Inc. (“EQRx” or the “Company”) (NASDAQ: EQRX), in connection with its proposed acquisition by Revolution Medicines, Inc. (NASDAQ: RVMD) (“Revolution Medicines”). Under the merger agreement, the Company’s shareholders will receive Revolution Medicines stock equal to $1.07 billion pursuant to a complex, blended formula providing for 20% thereof to be valued at $26 per share plus 80% thereof to be discounted 6% below the 5-day volume-weighted average Revolution Medicines share price around the time of the EQRx stockholder vote.
Join Case →